Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostatic Neoplasms: full-pipeline trial registry
19 of 66 indexed Prostatic Neoplasms trials are currently recruiting.
Corpus placement: #211 of 28,707 conditions by registered trial count.
66 US clinical trials · 19 currently recruiting · #211 of 28,707 conditions by registered trial count
Prostatic Neoplasms: 66 US clinical trials tracked, 19 recruiting.
Prostatic Neoplasms is the subject of 66 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 22 are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 8 of these trials.
Enrollment posture brief
Registry condition prostatic-neoplasms
OPEN 19 | RECR 29% | LATE 22 | EARLY 32 | RANK #211 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Cystic Fibrosis (29% recruiting · 170 trials)
Prostatic Neoplasms lists 19 open slots (29% of 66 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostatic Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostatic Neoplasms is recruiting below its size-band peers.
19 of 66 indexed trials (28.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostatic Neoplasms trials is spread across many organizations.
Janssen Research & Development accounts for 8 of 66 trials (12.1%). 39 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostatic Neoplasms enrolment sits around 144 participants.
Median target enrolment is 144 among the 66 trials that report a genuine target (sentinel values excluded). 25 of those (37.9%) plan for fewer than 100 participants.
-
Prostatic Neoplasms research is mostly interventional.
57 interventional and 9 observational studies make up this index (86.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
66 total, page 2 of 2
18F-DCFBC PET/CT in Prostate Cancer
National Cancer Institute (NCI)
NCT02190279
Prostate Mechanical Imager (PMI) Clinical Bridging Study
Artann Laboratories
NCT00822952
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Bayer
NCT02034552
EPO906 Therapy in Patients With Prostate Cancer
Novartis Pharmaceuticals
NCT00035113
Gallium-68 Citrate PET Used in Prostate Cancer
Rahul Aggarwal
NCT02391025
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
Janssen Research & Development
NCT02924766
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics
NCT00120939
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
David Oh
NCT03007732
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
AstraZeneca
NCT00055471
Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
University of Iowa
NCT02952469
Targeted Fusion Biopsy of the Prostate
Emory University
NCT02744534
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
Infinity Pharmaceuticals
NCT00564928
Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma
Cosmo Bioscience
NCT00061035
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
NCT05999968
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
Celgene
NCT00106301
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
GenSpera
NCT02381236
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 14 |
| Phase 3 | 21 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostatic Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostatic Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostatic Neoplasms page
66 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 19 Prostatic Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Prostatic Neoplasms trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostatic Neoplasms condition card totals 66 registered trials; most-linked intervention Prednisone; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.